Personalized Obesity Treatment Systems through Synergistic Combinations
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates a steroid sulfatase inhibitor composition with cutting-edge technologies like AI, IoT, and blockchain to create a personalized obesity treatment system, enhancing treatment efficacy and patient outcomes.
Background and Problem Solved
The original patent disclosed a composition for preventing or treating obesity or lipid-related metabolic disorders. However, it had limitations in terms of personalized treatment and data management. This new inventive concept addresses these limitations by combining the composition with advanced technologies to provide a more effective and tailored treatment approach.
Detailed Description of the Inventive Concept
The system consists of a wearable device for monitoring vital signs, a machine learning module for predicting treatment efficacy, and a composition comprising a steroid sulfatase inhibitor for administering a tailored dosage to a subject. The blockchain-based health data management system ensures secure and decentralized data storage, while the machine learning module optimizes lipid metabolism and predicts treatment outcomes. The wearable device and smart pill enable real-time monitoring and personalized treatment regimens.
Novelty and Inventive Step
The new claims introduce a synergistic combination of a steroid sulfatase inhibitor composition with AI, IoT, and blockchain technologies, providing a novel and non-obvious approach to personalized obesity treatment. The integration of these distinct technologies creates a more powerful system that enhances treatment efficacy and patient outcomes.
Alternative Embodiments and Variations
Alternative embodiments may include integrating the composition with other technologies like augmented reality or 5G networks. Variations may involve using different types of sensors or machine learning algorithms to optimize treatment outcomes.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the healthcare industry, particularly in the fields of obesity treatment, lipid metabolism, and personalized medicine. The target market includes pharmaceutical companies, healthcare providers, and patients seeking more effective and personalized treatment options.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, metabolic disease treatment, personalized medicine technologies with a focus on obesity and lipid metabolism interventions
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, biotechnology, or biomedical engineering, possessing expertise in drug development, metabolic disorder treatments, and emerging digital health technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with pharmaceutical compositions represents a predictable evolution of personalized medicine approaches. The combination of steroid sulfatase inhibitor treatments with AI, IoT, and blockchain technologies follows established trends in precision medicine for metabolic disorders. The technical variations represent incremental improvements that leverage known technological capabilities to enhance treatment monitoring and personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,533 |
|---|---|
| Title | Composition for preventing or treating obesity or lipid-related metabolic disorders |
| Assignee(s) | Nexyon Biotech Co., Ltd. |